Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

IPO Watch: Simcere Supplies High-End Generics In China

publication date: Apr 12, 2007
Company Angling For Partnerships With Western Companies -- Simcere Pharma (SCR) of China, a company that bills itself as a maker of branded generic drugs for the domestic (Chinese) market, has filed to make its IPO and list on the NYSE. The company focuses on first-to-market generics, including an anti-stroke drug and an anti-cancer medication. The Simcere portfolio of drugs has high margins, because they treat serious diseases or are in high demand. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital